Ivabradin Al

Ivabradine, the active ingredient in Ivabradin Al, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and for heart failure in patients with reduced ejection fraction.

GNH USA supplies Ivabradin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery across Europe, Asia, Africa and the Americas.

Ivabradine acts on the cardiac conduction system by selectively inhibiting the If current, and is used in specific cardiovascular conditions.

- Chronic stable angina pectoris: reduces frequency of angina attacks by lowering heart rate. - Heart failure (NYHA class II‑III): improves exercise capacity and reduces hospitalization risk by decreasing heart rate in patients with reduced ejection fraction.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: symptomatic slowing of heart rate. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Atrial fibrillation: new onset arrhythmia. - Severe bradycardia requiring medical intervention. - Allergic reactions: rash, pruritus, or angioedema.

When prescribing ivabradine, clinicians should observe several precautionary measures to minimise risk.

- Indication verification: ensure patient has chronic stable angina or heart failure with elevated heart rate. - Concomitant beta‑blocker use: avoid excessive heart‑rate reduction; adjust doses accordingly. - Visual assessment: screen for retinal disease before initiating therapy. - Hepatic impairment: use with caution in moderate to severe liver dysfunction. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Ivabradine interacts with several medicines that can alter its plasma concentration or additive cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels and risk of bradycardia. - Concomitant use with other heart‑rate‑lowering agents (e.g., digoxin, non‑DHP calcium channel blockers): can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure for additive hypotensive effect.